A phase I clinical trial (NCT03821935) [432] investigated the impact of blocking TGF-β activation by GARP using ABBV-151, an anti-GARP mAb, on cancer immunotherapy in combination with the anti-PD-1 MoAb Budigalimab. Here, LRRC32 is linked to cancer.